Selvita (787) Stock Overview

Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, analytical and solid state chemistry, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, inflammation, and fibrosis. In addition, the company provides drug development services, including development, validation, and transfer; quality control; small molecules analytical testing; stability testing; elemental impurities testing; pharmaceutical impurities identification, determination, and testing; nitrosamines determination and testing; pyrrolizidine alkaloids determination and testing; cleaning validation; bioequivalence; analytical support and equipment; ICH Q6B testing; physicochemical properties determination; binding properties and potency assays; therapeutic proteins production and development services. Further, it offers research and development services in the areas of agrochemistry analytical support, flavor and fragrance, and chemotypes. The company has a collaboration agreement with The University of Oxford to advance potential therapeutics for Parkinson's disease. Selvita S.A. was founded in 2007 and is headquartered in Kraków, Poland.